Birgitta Versluijs

49 Association between respiratory virus and alloimmune lung syndromes TABLE 1. Patient characteristics RV-positive RV-negative P Age at HSCT, median (range) in years 6.0 (0.5-19) 2.6 (0.2-21) NS Follow-up, median (range) in weeks 70 (4-230) 57 (4-192) NS Sex, n (%)  Male  Female 29 (53) 26 (47) 29 (53) 26 (47) NS Indication, n (%)*  Malignant  Nonmalignant 31 (56) 24 (44) 25 (46) 30 (54) NS HLA disparity, n (%)†  Matched  Mismatched 39 (71) 16 (29) 30 (54) 25 (46) .076 Number of HSCT, n (%)  First  Second  Third 52 (94) 3 (6) 0 (0) 50 (91) 4 (6) 1 (2) NS Conditioning, n (%)‡  TBI-based  Chemotherapy-based 21 (38) 34 (67) 12 (22) 43 (78) NS Donor relationship, n (%)  Family  Unrelated 18 (33) 37 (67) 15 (27) 40 (73) NS Graft source, n (%)  BM/PBSC  CB§ 43 (78) 12 (22) 34 (62) 21 (38) .061 HSCT indicates hematopoietic stem cell transplantation; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood; TBI, total body irradiation; NS, not significant. *Malignant indications: Acute lymphoblastic leukemia, 34; myelodysplastic syndrome, 9; acute myelogenous leukemia, 8; juvenile myelomonocytic leukemia, 1; lymphoma, 4. Nonmalignant indications: inborn errors of metabolism, 23; immune deficiency, 13; hemophagocytic lymphohistiocytosis, 5; BM failure, 11; others, 2. †Matched donor was defined as either 10 of 10 for BM/PBSC grafts molecularly typed or 6 of 6 for CB grafts based on intermediate resolution (HLA-A and HLA-B on serology and HLA-DR on high resolution). ‡Conditioning regimens: TBI-based (n = 33): Fractionated TBI (3x2x2 Gy) and etoposide 40 mg/kg, 29; thora- coabominal irradiation/cyclophosphamide 10 mg/kg)/fludarabine (90 mg/m 2 ), 2; TBI (7 Gy)/etoposide (40 mg/ kg), 1; TBI/thiotepa/etoposide, 1. Chemotherapy-based (n = 77): busulfan 480 mg/m 2 /cyclophosphamide 120 or 200 mg/kg, 46; busulfan 480 mg/m 2 /cyclophosphamide 120 mg/kg/melphalan 140 mg/m 2 , 17; busulfan 480 mg/m 2 /cyclophosphamide 120 mg/kg/etoposide 40 mg/kg, 3; busulfan 480 mg/m 2 /fludarabine 180 mg/m 2 , 3; busulfan 160 mg/m 2 /cyclophosphamide 40 mg/kg/fludarabine 90 mg/m 2 , 3; cyclophosphamide 120 mg/kg, 2; treosulfan 42 g/m 2 /etoposide 40 mg/kg/cyclophosphamide 120 mg/kg, 1; treosulfan 42 g/m 2 , 1; none, 1. Patients receiving an unrelated donor graft received serotherapy (thymoglobuline, 37; ATG-fresenius, 16; campath-1H, 3). §Median cell dose of CB: in nucleated cells, 7.8 (range, 2.7-20.0) x10 7 cells/kg; in CD34+ cells, 4.5 (range, 1.1-10.0) x10 5 cells/kg. All CB grafts were unrelated. One patient received a double CB graft. 3